AU2011227226B2 - Method for using a Bacillus subtilis strain for prophylaxis and treatment of gastro-intestinal conditions - Google Patents
Method for using a Bacillus subtilis strain for prophylaxis and treatment of gastro-intestinal conditions Download PDFInfo
- Publication number
- AU2011227226B2 AU2011227226B2 AU2011227226A AU2011227226A AU2011227226B2 AU 2011227226 B2 AU2011227226 B2 AU 2011227226B2 AU 2011227226 A AU2011227226 A AU 2011227226A AU 2011227226 A AU2011227226 A AU 2011227226A AU 2011227226 B2 AU2011227226 B2 AU 2011227226B2
- Authority
- AU
- Australia
- Prior art keywords
- bacillus subtilis
- composition
- subtilis qst713
- qst713
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 244000063299 Bacillus subtilis Species 0.000 title claims abstract description 79
- 235000014469 Bacillus subtilis Nutrition 0.000 title claims abstract description 79
- 238000000034 method Methods 0.000 title claims abstract description 42
- 238000011282 treatment Methods 0.000 title claims description 16
- 238000011321 prophylaxis Methods 0.000 title description 2
- 206010017943 Gastrointestinal conditions Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 66
- 230000036541 health Effects 0.000 claims abstract description 20
- 230000002708 enhancing effect Effects 0.000 claims abstract description 6
- 239000002207 metabolite Substances 0.000 claims description 30
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 25
- 206010012735 Diarrhoea Diseases 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 208000024891 symptom Diseases 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 208000035475 disorder Diseases 0.000 claims description 16
- 241001112696 Clostridia Species 0.000 claims description 14
- 208000010643 digestive system disease Diseases 0.000 claims description 14
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 14
- 244000052616 bacterial pathogen Species 0.000 claims description 13
- 230000012010 growth Effects 0.000 claims description 12
- 239000006041 probiotic Substances 0.000 claims description 12
- 235000018291 probiotics Nutrition 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 241000186781 Listeria Species 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 9
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 201000009840 acute diarrhea Diseases 0.000 claims description 7
- 235000013361 beverage Nutrition 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 244000005709 gut microbiome Species 0.000 claims description 5
- 241000193163 Clostridioides difficile Species 0.000 claims description 4
- 241000193403 Clostridium Species 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000000529 probiotic effect Effects 0.000 claims description 3
- 229960002181 saccharomyces boulardii Drugs 0.000 claims description 3
- 241000589876 Campylobacter Species 0.000 claims description 2
- 230000003187 abdominal effect Effects 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 claims description 2
- 241000510930 Brachyspira pilosicoli Species 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 28
- 206010009887 colitis Diseases 0.000 description 20
- 238000000855 fermentation Methods 0.000 description 20
- 230000004151 fermentation Effects 0.000 description 20
- 238000012360 testing method Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 230000037396 body weight Effects 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- 241000193830 Bacillus <bacterium> Species 0.000 description 12
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 244000052769 pathogen Species 0.000 description 11
- 210000001072 colon Anatomy 0.000 description 10
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 10
- 208000025865 Ulcer Diseases 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 229960004963 mesalazine Drugs 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 229960000598 infliximab Drugs 0.000 description 8
- 241000607142 Salmonella Species 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 210000004215 spore Anatomy 0.000 description 7
- 230000036269 ulceration Effects 0.000 description 7
- 241000589875 Campylobacter jejuni Species 0.000 description 6
- 241000193468 Clostridium perfringens Species 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 241000186779 Listeria monocytogenes Species 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000028070 sporulation Effects 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 108010028921 Lipopeptides Proteins 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 206010020565 Hyperaemia Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- 239000000304 virulence factor Substances 0.000 description 3
- 230000007923 virulence factor Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000186807 Listeria seeligeri Species 0.000 description 2
- 241000186814 Listeria welshimeri Species 0.000 description 2
- 241000533331 Salmonella bongori Species 0.000 description 2
- 241001138501 Salmonella enterica Species 0.000 description 2
- 241000607356 Salmonella enterica subsp. arizonae Species 0.000 description 2
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 210000004666 bacterial spore Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 235000015122 lemonade Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000017066 negative regulation of growth Effects 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- HUPDIVYMUZMPMO-UHFFFAOYSA-N 2,4,5-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC([N+]([O-])=O)=C([N+]([O-])=O)C=C1[N+]([O-])=O HUPDIVYMUZMPMO-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011118 depth filtration Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002036 drum drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940037395 electrolytes Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- -1 inulin Chemical class 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- RCIMBBZXSXFZBV-UHFFFAOYSA-N piromidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCCC1 RCIMBBZXSXFZBV-UHFFFAOYSA-N 0.000 description 1
- 244000000003 plant pathogen Species 0.000 description 1
- 108010069329 plipastatin Proteins 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 230000029054 response to nutrient Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000010563 solid-state fermentation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 239000006150 trypticase soy agar Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31499710P | 2010-03-17 | 2010-03-17 | |
| US61/314,997 | 2010-03-17 | ||
| PCT/US2011/028755 WO2011116155A1 (en) | 2010-03-17 | 2011-03-17 | Method for using a bacillus subtilis strain for prophylaxis and treatment of gastro-intestinal conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2011227226A1 AU2011227226A1 (en) | 2012-11-08 |
| AU2011227226B2 true AU2011227226B2 (en) | 2017-02-16 |
Family
ID=44072771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011227226A Active AU2011227226B2 (en) | 2010-03-17 | 2011-03-17 | Method for using a Bacillus subtilis strain for prophylaxis and treatment of gastro-intestinal conditions |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9457054B2 (enExample) |
| EP (1) | EP2547348B1 (enExample) |
| JP (1) | JP5830084B2 (enExample) |
| AU (1) | AU2011227226B2 (enExample) |
| DK (1) | DK2547348T3 (enExample) |
| ES (1) | ES2550059T3 (enExample) |
| MY (1) | MY161197A (enExample) |
| NZ (1) | NZ603065A (enExample) |
| PL (1) | PL2547348T3 (enExample) |
| WO (1) | WO2011116155A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021032975A1 (en) * | 2019-08-20 | 2021-02-25 | Sporegen Limitd | Formulations for prevention or reduction of c. difficile infections |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20120074A1 (es) | 2008-09-17 | 2012-02-26 | Agraquest Inc | Composicion que comprende cepa de bacillus subtilis para alimentar animales |
| DK2547348T3 (da) | 2010-03-17 | 2015-08-24 | Bayer Cropscience Lp | Fremgangsmåde til anvendelse af en bacillus subtilis-stamme til profylakse og behandling af mave-tarm-tilstande |
| JP2014518878A (ja) | 2011-05-24 | 2014-08-07 | バイエル クロップサイエンス エルピー | ポリエン系殺菌剤と非リボソーム型ペプチドの相乗的組み合わせ及び関連する使用方法 |
| CN104245943A (zh) * | 2012-02-21 | 2014-12-24 | 杜邦营养生物科学有限公司 | 包含来自枯草芽孢杆菌的发酵产物的组合物 |
| FR3007654B1 (fr) * | 2013-06-27 | 2015-07-10 | Lesaffre & Cie | Composition de solute de rehydratation orale contenant des probiotiques |
| FR3007655B1 (fr) * | 2013-06-28 | 2016-12-23 | Lesaffre & Cie | Souche bacillus subtilis pour le traitement et/ou la prevention de maladies inflammatoires chroniques |
| JP6440463B2 (ja) * | 2013-11-15 | 2018-12-19 | プリマハム株式会社 | 抗菌作用を有するバチルス・メチロトロフィカス |
| JP6671950B2 (ja) * | 2015-12-18 | 2020-03-25 | アサヒカルピスウェルネス株式会社 | 機能性胃腸症改善剤 |
| EP3645751A1 (en) * | 2017-06-30 | 2020-05-06 | Evonik Operations GmbH | Bacillus subtilis |
| US12194142B2 (en) | 2017-09-25 | 2025-01-14 | Deerland Enzymes, Inc. | Bacillus subtilis containing composition for treatment of gastrointestinal irregularity |
| MY202181A (en) | 2018-01-24 | 2024-04-14 | Omnigen Res Llc | Bacillus combination for administration to animals |
| US11278578B2 (en) * | 2018-09-02 | 2022-03-22 | Sanzyme Biologics Private Limited | Combination probiotic compositions and uses thereof |
| BE1027162B1 (nl) * | 2019-03-29 | 2020-11-05 | My Res Comm V | Bacillus coagulans en Bacillus subtilis voor de preventie en behandeling van functionele gastro-intestinale stoornissen |
| US11160838B2 (en) | 2019-08-09 | 2021-11-02 | Deerland Enzymes, Inc. | Antifungal and antimicrobial uses of Bacillus subtilis containing compositions |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6060051A (en) * | 1997-05-09 | 2000-05-09 | Agraquest, Inc. | Strain of bacillus for controlling plant diseases and corn rootworm |
| US6103228A (en) * | 1997-05-09 | 2000-08-15 | Agraquest, Inc. | Compositions and methods for controlling plant pests |
| WO2010033714A1 (en) * | 2008-09-17 | 2010-03-25 | Agraquest, Inc. | Method for using a bacillus subtilis strain to enhance animal health |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62232343A (ja) | 1986-04-01 | 1987-10-12 | Kyodo Shiryo Kk | 幼豚用配合飼料 |
| JPS63209580A (ja) | 1987-02-25 | 1988-08-31 | Karupisu Shokuhin Kogyo Kk | バチルス・ズブチリスｃ−３１０２ |
| KR930001383B1 (ko) | 1990-10-31 | 1993-02-27 | 재단법인 한국화학연구소 | 신규의 바실러스 서브틸리스 아종 및 이로부터 생산되는 항진균 물질 krf-001 복합체의 용도 |
| US5785990A (en) | 1995-07-10 | 1998-07-28 | Merrick's, Inc. | Feed fortifier and enhancer for preruminant calves and method of using same |
| JP2979294B2 (ja) | 1996-10-02 | 1999-11-15 | カルピス株式会社 | 鳥類卵殻強度増強剤 |
| US6015553A (en) | 1997-08-22 | 2000-01-18 | Agraquest, Inc. | Bacillus subtilis strain for controlling insect and nematode pests |
| JP3260111B2 (ja) | 1997-10-09 | 2002-02-25 | 伊藤忠飼料株式会社 | 鳥類の給餌中止時の体重減少抑制方法及び腸内有害細菌減少方法 |
| US6461607B1 (en) | 1998-08-24 | 2002-10-08 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
| JP2000166583A (ja) | 1998-10-02 | 2000-06-20 | Shin Nihonsha:Kk | 枯草菌等が産生する無機物及びその酸塩と副産物及びその誘導体 |
| GB0124580D0 (en) | 2001-10-12 | 2001-12-05 | Univ Reading | New composition |
| GB0130789D0 (en) | 2001-12-21 | 2002-02-06 | King S College London | Application of spores |
| AR040927A1 (es) | 2002-04-10 | 2005-04-27 | Cooperativas Argentinas Cooper | Alimento para la crianza de vacunos neonatos y procedimiento de utilizacion. |
| AT413191B (de) | 2002-10-11 | 2005-12-15 | Erber Ag | Futtermittel- und/oder trinkwasserzusatz für nutztiere |
| US7247299B2 (en) * | 2002-11-27 | 2007-07-24 | Kemin Industries, Inc. | Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens |
| EP1472933A1 (en) | 2003-05-01 | 2004-11-03 | Chr. Hansen A/S | Improving health and/or nutritional status of an aquatic animal by aid of Bacillus licheniformis |
| WO2005010052A2 (en) | 2003-07-24 | 2005-02-03 | Cargill, Incorporated | Enhanced steep-water |
| RU2266747C1 (ru) | 2004-03-22 | 2005-12-27 | Кубанский государственный аграрный университет | Пробиотическая композиция для животных и птицы |
| JP2007054041A (ja) | 2005-07-29 | 2007-03-08 | Yodorinon Kenkyusho:Kk | 養鶏飼料並びに卵 |
| US20080057047A1 (en) | 2005-11-29 | 2008-03-06 | Benedikt Sas | Use of bacillus amyloliquefaciens PB6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases |
| US7754469B2 (en) * | 2005-11-30 | 2010-07-13 | Agtech Products, Inc | Microorganisms and methods for treating poultry |
| JP4968816B2 (ja) * | 2006-03-08 | 2012-07-04 | 日本曹達株式会社 | バチルス属細菌の芽胞形成方法 |
| US20070298013A1 (en) * | 2006-06-23 | 2007-12-27 | Altman Jay A | Animal Nutritional Supplement and Method |
| EA019915B1 (ru) * | 2007-09-20 | 2014-07-30 | Басф Се | Фунгицидная композиция для борьбы с фитопатогенными вредными грибами |
| US8227235B2 (en) | 2008-12-10 | 2012-07-24 | Alpharma, Llc | Compositions and methods for controlling diseases in animals |
| DK2547348T3 (da) | 2010-03-17 | 2015-08-24 | Bayer Cropscience Lp | Fremgangsmåde til anvendelse af en bacillus subtilis-stamme til profylakse og behandling af mave-tarm-tilstande |
-
2011
- 2011-03-17 DK DK11710383.8T patent/DK2547348T3/da active
- 2011-03-17 US US13/582,359 patent/US9457054B2/en active Active
- 2011-03-17 NZ NZ603065A patent/NZ603065A/en not_active IP Right Cessation
- 2011-03-17 JP JP2013500197A patent/JP5830084B2/ja active Active
- 2011-03-17 WO PCT/US2011/028755 patent/WO2011116155A1/en not_active Ceased
- 2011-03-17 EP EP20110710383 patent/EP2547348B1/en active Active
- 2011-03-17 PL PL11710383T patent/PL2547348T3/pl unknown
- 2011-03-17 AU AU2011227226A patent/AU2011227226B2/en active Active
- 2011-03-17 MY MYPI2012700660A patent/MY161197A/en unknown
- 2011-03-17 ES ES11710383.8T patent/ES2550059T3/es active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6060051A (en) * | 1997-05-09 | 2000-05-09 | Agraquest, Inc. | Strain of bacillus for controlling plant diseases and corn rootworm |
| US6103228A (en) * | 1997-05-09 | 2000-08-15 | Agraquest, Inc. | Compositions and methods for controlling plant pests |
| WO2010033714A1 (en) * | 2008-09-17 | 2010-03-25 | Agraquest, Inc. | Method for using a bacillus subtilis strain to enhance animal health |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021032975A1 (en) * | 2019-08-20 | 2021-02-25 | Sporegen Limitd | Formulations for prevention or reduction of c. difficile infections |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011116155A1 (en) | 2011-09-22 |
| AU2011227226A1 (en) | 2012-11-08 |
| PL2547348T3 (pl) | 2015-11-30 |
| ES2550059T3 (es) | 2015-11-04 |
| EP2547348B1 (en) | 2015-05-20 |
| NZ603065A (en) | 2014-12-24 |
| JP5830084B2 (ja) | 2015-12-09 |
| EP2547348A1 (en) | 2013-01-23 |
| JP2013522315A (ja) | 2013-06-13 |
| US20120328571A1 (en) | 2012-12-27 |
| DK2547348T3 (da) | 2015-08-24 |
| US9457054B2 (en) | 2016-10-04 |
| MY161197A (en) | 2017-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011227226B2 (en) | Method for using a Bacillus subtilis strain for prophylaxis and treatment of gastro-intestinal conditions | |
| JP4623896B2 (ja) | ヒトおよび動物に使用される細菌株、加工された植物抽出物およびプロバイオティック組成物 | |
| JP5718916B2 (ja) | 新規なラクトバチルス・プランタラム及びこれを含む組成物 | |
| KR101772870B1 (ko) | 프로바이오틱 활성을 갖는 신규 락토바실러스 플란타럼 및 이의 용도 | |
| US20080102061A1 (en) | Use hydrolyzed medium containing microorganisms medicinally | |
| JP2007518693A (ja) | 安定な液体プロバイオティクス組成物、その調製および適用 | |
| JP2002523372A (ja) | 共生乳酸産生細菌およびその使用 | |
| CN104789511B (zh) | 一株具有广谱抑菌特性的植物乳杆菌ab-2及其应用 | |
| CN111011856A (zh) | 用于缓解胃病的组合物、其制备方法及用于缓解胃病的食品 | |
| KR20180011490A (ko) | 프로바이오틱 활성을 갖는 신규 락토바실러스 퍼멘텀 및 이의 용도 | |
| AU3472693A (en) | Probiotic for control of salmonella | |
| KR101000364B1 (ko) | 생존율 증강용 이중 코팅 방법 | |
| CN114468306A (zh) | 凝结芽孢杆菌bc99在制备缓解结肠炎制品或免疫调节制品方面的用途 | |
| KR102391832B1 (ko) | 클로스트리디오이데스 디피실 억제용 유산균 복합 균주 및 이를 포함하는 장염증 예방, 치료 또는 개선용 조성물 | |
| KR20240037257A (ko) | 위장관 장애의 치료에서의 사용을 위한 생리학적으로 허용되는 효모 조성물 | |
| JPH06166626A (ja) | 生菌粉末 | |
| CN117568211A (zh) | 一株具有抗沙门氏菌感染功能的植物乳植杆菌goldgut-lp618及其应用 | |
| KR102452957B1 (ko) | 프로바이오틱스 균주를 유효성분으로 포함하는 클로스트리디오이데스 디피실레 감염을 예방 또는 치료하기 위한 조성물 | |
| KR102617297B1 (ko) | 클로스트리디움 디피실리 감염의 치료 또는 예방용 조성물 | |
| JP2006180836A (ja) | 食中毒菌感染を抑制する乳酸菌、ならびにそれを含む発酵物、食品および医薬組成物 | |
| KR100483369B1 (ko) | 파일로리 및 리스테리아 모노사이토진의 생육을 억제하는 항균활성물질을 생산하는 페디오코커스 펜토사세우스ｃｂｔ-8로 명명되는 유산균주, 이를 이용한 항균특성을 갖는 항균물질 제조 방법 및 그 제조된 항균물질 기능성식품 및 의약품에 이용하는 방법 | |
| KR101772875B1 (ko) | 프로바이오틱 활성을 갖는 신규 락토바실러스 플란타럼 및 이의 용도 | |
| KR20220008218A (ko) | 염증성 장질환 예방 또는 치료용 조성물 | |
| KR100855022B1 (ko) | 락토바실러스 파라플란타룸 ｋｎｕｃ２５를 포함하는헬리코박터 파이로리 생육 억제용 조성물 | |
| KR101772872B1 (ko) | 프로바이오틱 활성을 갖는 신규 락토바실러스 플란타럼 및 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: BAYER CROPSCIENCES LP Free format text: FORMER APPLICANT(S): AGRAQUEST, INC. |
|
| TH | Corrigenda |
Free format text: IN VOL 31 , NO 4 , PAGE(S) 475 UNDER THE HEADING ASSIGNMENTS BEFORE GRANT, SECTION 113 - 2011 UNDER THE NAME BAYER CROPSCIENCES LP, APPLICATION NO. 2011227226, UNDER INID (71) CORRECT APPLICANT NAME TO READ BAYER CROPSCIENCE LP |
|
| FGA | Letters patent sealed or granted (standard patent) |